US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,299.47

-72.4186-5.28%

Number of Gainers:1

Number of Losers:2

Number of Flat:- -

PE:- -

High:1,351.68

Open:1,351.68

Low:1,297.72

Close:1,371.88

Loading ...

11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year

Gilead : RBC Cuts Target Price to $89 From $90

THOMSON REUTERS

Novartis Gets FDA Accelerated Approval for Vanrafia

MT Newswires Live

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

Novartis gets FDA accelerated approval for Vanrafia

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag

BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar

Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar

THOMSON REUTERS

Biotech stocks slide as Marks resignation seen being negative for sector

Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV

ACCESS Newswire

Bluebird Bio Shares Rise After Non-Binding Offer From Ayrmid

Alphabet's Isomorphic Labs Unit Raises $600 Million for AI-Based Drug Development

MT Newswires Live

Fiery Resignation of Top FDA Official Sparks Biotech Selloff -- Barrons.com

BUZZ-Bluebird bio rises on non-binding bid for up to $110.5 million

Bluebird bio receives non-binding bid for up to $110.5 million

BUZZ-Bluebird Bio shares rally 11% in late trade on buyout offer

Bluebird Bio Reviewing Competing Buyout Offer From Ayrmid for Up to $110.5 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4578/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1299.4656,"timestamp":1743796799999,"preClose":1371.8842,"halted":0,"volume":16665212,"delay":0,"changeRate":-0.052788,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-72.418579,"latestTime":"04-04 16:00:00 EDT","open":1351.6838,"high":1351.6838,"low":1297.722,"amount":1796069109.858636,"amplitude":0.039334,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.422342,"peRate":28.199286,"turnoverRate":0.00545,"increases":1,"decrements":2,"flats":0,"marketCap":334470738988,"floatMarketCap":324435868480},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1351.6838,"amplitude":0.039334,"preClose":1371.8842,"low":1297.722,"pbRate":"5.422342","latestPrice":1299.4656,"volume":16665212,"delay":0,"open":1351.6838,"prevYearClose":1164.883,"prevWeekClose":1370.9408,"prevMonthClose":1364.0579,"prevQuarterClose":1364.0579,"fiveDayClose":1370.9408,"twentyDayClose":1419.5145,"sixtyDayClose":1169.3091,"secType":"PLATE","market":"US","turnoverRate":0.00545,"peRate":28.199286,"marketCap":334470738988,"floatMarketCap":324435868480,"timestamp":1743796799999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":1,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524224602","title":"11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2524224602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524224602?lang=en_us&edition=fundamental","pubTime":"2025-04-04 13:00","pubTimestamp":1743742800,"startTime":"0","endTime":"0","summary":"Biotechnology may be the stuff that dreams are made of, but more recently, the sector has been a nightmare for investors.Biotech is coming off one of its worst weeks in several years after the SPDR S&P Biotech exchange-traded fund fell about 7% following the resignation of a key Food and Drug Administration regulator, Peter Marks, who oversaw approval processes for vaccines and novel biotech therapies. There were also fresh budget cuts at the agency and the departure of other drug regulators. It didn't help that the Trump administration's top health official, Robert F. Kennedy Jr, is a vaccine skeptic and lukewarm on traditional medicine.Even though they continue to lead the world in innovation, American companies face a growing threat from Chinese biotechs that have stron","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU1894683264.USD","VRTX","LU2242646821.SGD","LU0225771236.USD","LU2362540622.SGD","IE00BJJMRZ35.SGD","LU1929549753.HKD","LU1934455277.USD","LU0058720904.USD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","IE00B894F039.SGD","IE00BLSP4239.USD","LU0211331839.USD","LU1023059063.AUD","BK4585","LU1699723380.USD","IE00BJT1NW94.SGD","MRK","BK4578","LU0234570918.USD","LU0889565916.HKD","AMGN","LU1917777945.USD","LU0985320562.USD","LU0266013472.USD","LU1069347547.HKD","LU1116320737.USD","LU0306807586.USD","BK4588","LU2242652126.USD","LU0208291251.USD","LU1061106388.HKD","IE00B3T34201.USD","BK4599","IE00B2B36J28.USD","LU2417539215.USD","SG9999003800.SGD","BK4568","SG9999001176.SGD","GILD","LU0965509101.SGD","BK4533","LU0868494617.USD","LU2361044865.SGD","SG9999015341.SGD","LU2106854487.HKD","IE00BBT3K403.USD"],"gpt_icon":1},{"id":"2524293880","title":"Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2524293880","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524293880?lang=en_us&edition=fundamental","pubTime":"2025-04-04 00:10","pubTimestamp":1743696643,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  on Wednesday granted accelerated approval for Novartis AG’s  Vanrafia  to reduce proteinuria in adults with primary immunoglobulin A nephropathy  at risk of rapid disease progression.Vanrafia is a once-daily, non-steroidal, oral treatment that can be added to supportive care, including a renin-angiotensin system inhibitor with or without a sodium-glucose co-transporter-2 inhibitor.Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase 3 ALIGN study measuring the reduction of proteinuria at 36 weeks compared to placebo.Also Read: FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals. It has not been established whether Vanrafia slows kidney function decline in patients with IgAN.The continued approval of Vanrafia may be contingent upon verifying clinical benefit from the ongoing Phase 3 ALIGN study evaluating whether Vanrafia slows disease progression as measured by estimated glomerular filtration rat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-secures-third-fda-approval-161043441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0070302665.USD","LU0208291251.USD","IE00BJJMRZ35.SGD","BK4578","NVS","BK4532","IE00BJT1NW94.SGD","LU0211331839.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","BK4585","BK4007","BK4588","LU0320765489.SGD"],"gpt_icon":0},{"id":"2524253392","title":"Gilead : RBC Cuts Target Price to $89 From $90","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253392?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:33","pubTimestamp":1743680011,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH11E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0320765992.SGD","LU0234570918.USD","GILD","LU1585245621.USD","LU1571399168.USD","IE0002270589.USD","BK4568","LU1430594728.SGD","LU2089984988.USD","BK4578","IE00BKVL7J92.USD","LU1066051498.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4585","IE00B3T34201.USD","LU2087621335.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4583","BK4588","BK4139","LU2468319806.SGD","BK4566","LU1839511570.USD","LU0289739699.SGD","BK4532","IE00BSNM7G36.USD","LU0058720904.USD","BK4550"],"gpt_icon":0},{"id":"2524128499","title":"Novartis Gets FDA Accelerated Approval for Vanrafia","url":"https://stock-news.laohu8.com/highlight/detail?id=2524128499","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524128499?lang=en_us&edition=fundamental","pubTime":"2025-04-03 16:41","pubTimestamp":1743669711,"startTime":"0","endTime":"0","summary":"Novartis  said late Wednesday the US Food and Drug Administration granted accelerated approval for Vanrafia to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, at risk of rapid disease progression.IgAN is a progressive, rare kidney disease.Data from an ongoing phase III showed that Vanrafia achieved proteinuria reduction of about 36%, compared with placebo, with improvements seen at week six and sustained through week 36, as well as favorable safety, the company said.It has not been established whether Vanrafia slows kidney function decline in patients with IgAN, the company said, adding that the continued approval could depend on longer term data from the ongoing phase III study, which will evaluate whether Vanrafia slows disease progression based on estimated glomerular filtration rate decline, with results expected in 2026.Novartis shares were up 1.3% in recent premarket activity Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4578","BK4585","LU0070302665.USD","IE00B4R5TH58.HKD","LU0208291251.USD","BK4007","BK4532","IE00BJT1NW94.SGD","NVS","IE00B2B36J28.USD","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0211331839.USD","IE0002141913.USD","BK4588","IE0009355771.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2524832162","title":"Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2524832162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524832162?lang=en_us&edition=fundamental","pubTime":"2025-04-03 15:51","pubTimestamp":1743666660,"startTime":"0","endTime":"0","summary":"0751 GMT - Big Pharma stocks are up after U.S. President Trump exempted pharmaceuticals for now from his reciprocal tariffs on global imports. \"It is still somewhat unclear whether the broader reaching 10% baseline tariffs could still be levied against imported drugs and vaccines, in our view,\" Shore Capital analyst Sean Conroy says in a note. Likewise, Bryan Garnier Research analysts say in a note that the pharma industry is left uncertain about an actual tariff risk given Trump's mixed remarks that drugmakers \"will come roaring back to the U.S., because if they don't, they got a big tax to pay.\" Novartis and Sanofi are up 0.6% and 0.3%, respectively. The U.K's AstraZeneca and GSK rose 1% and 1.6%, respectively. Swiss pharma giant Roche is down 2.3% after its multiple-sclerosis drug Ocrevus failed to meet its primary endpoint. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","LU0320765992.SGD","LU2417539215.USD","LU0889565916.HKD","LU0211331839.USD","IE00BFTCPJ56.SGD","RHHBY","AZN","BK4578","IE0002141913.USD","LU0109394709.USD","IE00B2B36J28.USD","BK4568","LU2236285917.USD","LU0320765489.SGD","LU2462157665.USD","LU0070302665.USD","BK4532","SNY","BK4007","IE0009355771.USD","BK4588","GSK","IE00BJJMRZ35.SGD","BK4585","03165","IE00BFXG1179.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","NVS","GSK.UK","LU0208291251.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2524142759","title":"Novartis gets FDA accelerated approval for Vanrafia","url":"https://stock-news.laohu8.com/highlight/detail?id=2524142759","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524142759?lang=en_us&edition=fundamental","pubTime":"2025-04-03 08:50","pubTimestamp":1743641410,"startTime":"0","endTime":"0","summary":"Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor antago...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-gets-fda-accelerated-approval-for-vanrafia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-gets-fda-accelerated-approval-for-vanrafia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0208291251.USD","BK4578","BK4588","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0070302665.USD","BK4007","BK4585","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4532","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0320765489.SGD","NVS","LU0211331839.USD"],"gpt_icon":0},{"id":"2524252694","title":"Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2524252694","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524252694?lang=en_us&edition=fundamental","pubTime":"2025-04-03 06:00","pubTimestamp":1743631216,"startTime":"0","endTime":"0","summary":"Gilead Sciences  ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.67% for the day. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 0.87%.Shares of the HIV and hepatitis C drugmaker have depreciated by 3.02% over the course of the past month, outperforming the Medical sector's loss of 5.32% and the S&P 500's loss of 5.28%.Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company plans to announce its earnings on April 24, 2025. The company is forecasted to report an EPS of $1.73, showcasing a 231.06% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $6.8 billion, indicating a 1.67% upward movement from the same quarter last year.The Zacks Industry Rank gauges the strength of our industry","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-ascends-remains-220016973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","BK4583","BK4566","BK4550","GILD","LU2468319806.SGD","LU0109394709.USD","LU0320765992.SGD","BK4568","IE00B19Z3581.USD","BK4532","BK4585","IE00BKVL7J92.USD","LU0234570918.USD","IE00B3T34201.USD","BK4588","IE00B19Z3B42.SGD","LU1571399168.USD","LU0889565916.HKD","LU0058720904.USD","IE0002270589.USD","LU1585245621.USD","LU0289739699.SGD","BK4139","LU1430594728.SGD","LU2089984988.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","BK4578","IE00B7SZLL34.SGD","LU1066053197.SGD","LU1839511570.USD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4534","LU1989771016.USD","CORT","LU1585245621.USD","OS","LU2125154935.USD","LU0321505868.SGD","IE00BJJMRZ35.SGD","LU0306806265.USD","LU0321505439.SGD","LU2242646821.SGD","BK4588","LU1718418525.SGD","BK4556","BK4585","LU0225284248.USD","EXEL","LU1571399168.USD","LU0566484027.USD","PFS","LU0456855351.SGD","BK4578","LU1868836591.USD","BLUE","LU1093756168.USD","LU2242652126.USD","LU2125154778.USD","BK4007","BK4532","LU1074936037.SGD","IE00B2B36J28.USD","LU0306807586.USD","LU1670711123.USD","LU1868836757.USD","LU0096364046.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1093756325.SGD","LU0985481810.HKD","LU1670710588.SGD","LU1670710661.SGD","LU0882574055.USD","BMY","BK4505","AXSM","IE00BSNM7G36.USD","LU1670711040.USD","LU2360032135.SGD","LU1323610961.USD","BK4097"],"gpt_icon":1},{"id":"2524581497","title":"APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2524581497","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524581497?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:11","pubTimestamp":1743599460,"startTime":"0","endTime":"0","summary":"A filing accepted under the regulatory body’s Priority Review pathway reduces the review period to six months from the standard 10 months. This status is awarded to marketing applications for medicines intended to treat serious conditions and that, if approved, would offer a substantial improvement in safety, effectiveness, prevention, or diagnosis of such conditions.A final decision from the FDA is expected on July 28, 2025.Please note that Empaveli is approved in the United States for the treatment of paroxysmal nocturnal hemoglobinuria . The drug is also approved in Europe under the brand name Aspaveli for the same indication.Year to date, shares of Apellis have plunged 28.9% against theindustry’s 2.4% growth.In the VALIANT study, Empaveli was overall well-tolerated with a consistent safety profile. Adverse events were mostly mild to moderate in severity.Novartis recently announced that the FDA has approved Fabhalta for a third indication, C3G, to reduce proteinuria.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/apls-empaveli-snda-2-rare-131100793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211331839.USD","IE0009355771.USD","LU0566484027.USD","LU1093756168.USD","BAYRY","LU0070302665.USD","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4578","IE0002141913.USD","LU1559883803.SGD","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","BK4505","NVS","BK4585","BK4007","CORT","APLS","BK4139","BK4532","LU1093756325.SGD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2524467518","title":"BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467518","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467518?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:03","pubTimestamp":1743595395,"startTime":"0","endTime":"0","summary":"BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, AvatarApril 2 (Reuters) - bluebird bio Inc BLUE.O:XCELLBIO:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BLUE","BK4139","BK4556"],"gpt_icon":0},{"id":"2524467894","title":"Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467894?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:02","pubTimestamp":1743595360,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","BK4556","BLUE","BK4139"],"gpt_icon":0},{"id":"2524491531","title":"Biotech stocks slide as Marks resignation seen being negative for sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2524491531","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524491531?lang=en_us&edition=fundamental","pubTime":"2025-04-01 23:50","pubTimestamp":1743522637,"startTime":"0","endTime":"0","summary":"Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors.Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.“NOT GOOD” FOR BIOTECH SECTOR: RBC Capital believes the resignation of the head of the FDA’s Center for Biologics Evaluation and Research, Peter Marks, is “not good for the biotech industry even beyond vaccines.” Marks had been a key advocate for more flexible, efficient approval processes for drugs, particularly those for orphan diseases such as gene therapies, the firm tells investors in a research note.PRICE ACTION: In mornin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/biotech-stocks-slide-marks-resignation-155037694.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stocks-slide-marks-resignation-155037694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SRPT","IE0009355771.USD","VERV","NGNE","RCKTW","NTLA","LU1066051498.USD","LU2468319806.SGD","LU2023250504.SGD","MRNA","RCKT","LU0058720904.USD","BK4568","IE00B4R5TH58.HKD","DYN","RGNX","DTIL","BK4551","LU0823416689.USD","MGTX","VRTX","IE00BZ9MQY76.HKD","RNA","IE0002141913.USD","BEAM","LU0320765992.SGD","IE00BFTCPJ56.SGD","GLPG","REGN","KPTI","PCRX","LU2462157665.USD","BK4532","PRME","TSHA","IE00B3T34201.USD","LU0417517546.SGD","MGX","PTCT","LU1035775433.USD","FDMT","CRSP","LU1066053197.SGD","LU1571399168.USD","BK4007","LEGN","LU2362540622.SGD","LU1430594728.SGD","BK4139","GILD","BK4578","LU1069344957.HKD"],"gpt_icon":1},{"id":"2524423201","title":"Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2524423201","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524423201?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:55","pubTimestamp":1743512100,"startTime":"0","endTime":"0","summary":"NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years into his virology research career at Gilead and the first daily single tablet regimen for HIV treatment was still awaiting approval. Treatment options for people living with HIV at the time were a raft of daily medications that often carried intolerable side-effects, or the virus became resistant to the medications.\"That's what kept the research team at Gilead awake and stirred our urgent imperative to create something different,\" recalls Tomas, now Senior Vice President, Research Virology.Ten arduous years later, the researchers made significant progress toward their goal by creating a molecule that has the potential to help revolutionize the fight against HIV.Fittingly, Breakthrough, The Quest for Life-Changing Medicines is the name of a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discovering-breakthrough-gilead-long-standing-125500596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0289739699.SGD","LU1430594728.SGD","LU1066053197.SGD","LU2468319806.SGD","LU0109394709.USD","BK4583","IE00B19Z3581.USD","LU1066051498.USD","LU2087621335.USD","LU2089984988.USD","IE00BKVL7J92.USD","BK4139","LU1839511570.USD","LU0234570918.USD","LU1585245621.USD","GILD","LU0058720904.USD","LU0889565916.HKD","BK4588","IE0002270589.USD","IE00BSNM7G36.USD","BK4585","IE00B7SZLL34.SGD","BK4566","IE00B19Z3B42.SGD","IE00B3T34201.USD","BK4578","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4568","BK4550","LU1571399168.USD"],"gpt_icon":0},{"id":"2523470619","title":"Bluebird Bio Shares Rise After Non-Binding Offer From Ayrmid","url":"https://stock-news.laohu8.com/highlight/detail?id=2523470619","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523470619?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:52","pubTimestamp":1743429120,"startTime":"0","endTime":"0","summary":"Bluebird bio shares were 23% higher, at $5.03, after the company said it received an unsolicited, non-binding written acquisition proposal from Ayrmid.Ayrmid has offered to buy bluebird for an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable upon achievement of a net sales milestone, said Somerville, Mass.-based bluebird on Monday.On Feb. 21, bluebird agreed to be bought and taken private by funds managed by global investment firms Carlyle and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.Bluebird previously engaged in discussions with Ayrmid as part of its comprehensive review of strategic alternatives, although Ayrmid didn't submit any proposal to bluebird as part of that process, bluebird said.Bluebird said its board of directors is reviewing the Ayrmid Proposal in consultation with its legal and financial advisors.The stock hit","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bluebird Bio Shares Rise After Non-Binding Offer From Ayrmid","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","BLUE","BK4578"],"gpt_icon":0},{"id":"2523944917","title":"Alphabet's Isomorphic Labs Unit Raises $600 Million for AI-Based Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2523944917","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523944917?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:09","pubTimestamp":1743426567,"startTime":"0","endTime":"0","summary":"Alphabet's  artificial intelligence-based drug discovery unit Isomorphic Labs said Monday it raised $600 million in its first external funding round to develop its AI drug design engine and support drug candidates into clinical testing.The investment, led by Thrive Capital with participation from GV and Alphabet, is expected to support AI research, the company said, adding that it has internal drug discovery programs in oncology and immunology, as well as collaborations with Eli Lilly  and Novartis .Isomorphic Labs said it also plans to expand its workforce.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1868836757.USD","IE00B3S45H60.SGD","LU0965509010.AUD","LU0426412945.USD","LU0345774391.USD","LU1720051108.HKD","USJW.SI","GB00BDT5M118.USD","BK4578","GOOGL","LU1670628061.USD","LU1791710400.SGD","LU2756315318.SGD","LU0208291251.USD","LLY","IE00BMPRXN33.USD","LU1043141123.HKD","LU0985320562.USD","LU0672654240.SGD","LU2360106947.USD","LU0557290698.USD","IE00BJTD4N35.SGD","IE00BFSS8Q28.SGD","LU0048584097.USD","IE00BYQQ9H92.USD","LU2168563687.JPY","LU2361044949.HKD","BK4077","GOOG","LU0708995401.HKD","LU1116320737.USD","LU0820561818.USD","LU0109391861.USD","LU1868837136.USD","LU1496350171.SGD","LU2362541273.HKD","SG9999013999.USD","LU0267386448.USD","LU1023059063.AUD","LU0215105999.USD","LU1496350502.SGD","BK4576","LU1303367103.USD","LU0029864427.USD","LU2552382058.USD","LU0302445910.USD","NVS","LU1629891620.HKD","LU0289941410.SGD","LU0175139822.USD"],"gpt_icon":1},{"id":"2523416079","title":"Fiery Resignation of Top FDA Official Sparks Biotech Selloff -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2523416079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523416079?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:54","pubTimestamp":1743425640,"startTime":"0","endTime":"0","summary":"The dramatic resignation Friday night of a top Food and Drug Administration official triggered selling in biotech stocks, with shares of drugmakers Moderna and Sarepta Therapeutics tumbling early on Monday.Dr. Peter Marks, who led the FDA's Center for Biologics Evaluation and Research, was perhaps the best-known official within the agency. His support for moving quickly to approve medicines for rare diseases has been pivotal to the fates of a long list of biotech companies.Marks was also deeply involved in Operation Warp Speed, the effort during the first Trump administration to develop a Covid-19 vaccine. Marks famously suggested the name for the project, a nod to the Star Trek television series, of which he is reportedly a big fan.In a resignation letter that the New York Times published Friday, Marks indicated he had stepped down over disputes with Robert F. Kennedy Jr., secretary of the U.S. Department of Health and Human Services, regarding vaccine safety,Other biotechs that lost ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","BK4533","BK4551","BK4583","IE00B2B36J28.USD","IE0002270589.USD","LU2087621335.USD","LU0289739699.SGD","BK4139","LU0109394709.USD","BK4534","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU0234570918.USD","BK4548","BK4566","BK4585","LU1571399168.USD","BK4588","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU0889565916.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","GILD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU1585245621.USD","SRPT","IE00BJT1NW94.SGD","LU1066053197.SGD","BK4550","BK4532","BK4535","BK4568","IE00BKVL7J92.USD","BK4501","IE0002141913.USD","LU0320765992.SGD","LU1839511570.USD","LU2468319806.SGD","BK4578","IE00BJJMRZ35.SGD","MRNA","LU2089984988.USD","IE00B3T34201.USD","LU1066051498.USD"],"gpt_icon":1},{"id":"2523159229","title":"BUZZ-Bluebird bio rises on non-binding bid for up to $110.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523159229","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523159229?lang=en_us&edition=fundamental","pubTime":"2025-03-31 17:58","pubTimestamp":1743415095,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird bio rises on non-binding bid for up to $110.5 million** Gene therapy maker Bluebird Bio's BLUE.O shares rise 10% to $4.49 premarket** BLUE said late on Friday it received a non-binding offer from privately held UK company Ayrmid for up to $110.5 million** Ayrmid offered to acquire bluebird for $4.50 per share upfront, totaling about $43.8 million, according to Reuters calculations** Ayrmid also offered an additional $6.84 per share, representing about $66.6 million, contingent upon bluebird achieving certain sales milestones** In February, BLUE said it had agreed to be taken private by Carlyle Group <CG.O> and SK Capital Partners, for $3 per share upfront along with the same $6.84 per share, contingent upon it achieving certain sales milestones** As of last close, BLUE has fallen 84% in the past 12 months","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL6N3QE0DU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BK4556","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4135","IE00BGHQF748.EUR","CG","BLUE","BK4139"],"gpt_icon":0},{"id":"2523639566","title":"Bluebird bio receives non-binding bid for up to $110.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523639566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523639566?lang=en_us&edition=fundamental","pubTime":"2025-03-29 05:39","pubTimestamp":1743197942,"startTime":"0","endTime":"0","summary":"Bluebird bio receives non-binding bid for up to $110.5 million March 28 (Reuters) - Gene therapy maker bluebird bio BLUE.O said on Friday it had received a non-binding offer from peer Ayrmid for up to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL3N3QB1K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4135","IE00BGHQF748.EUR","BK4556","CG","BLUE","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4578"],"gpt_icon":0},{"id":"2523636606","title":"BUZZ-Bluebird Bio shares rally 11% in late trade on buyout offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523636606","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523636606?lang=en_us&edition=fundamental","pubTime":"2025-03-29 05:20","pubTimestamp":1743196812,"startTime":"0","endTime":"0","summary":"BUZZ-Bluebird Bio shares rally 11% in late trade on buyout offer** Shares in gene therapy co Bluebird Bio BLUE.O up 11% at $4.54 in after-the-bell trading after it confirmed receipt of unsolicited buy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL2N3QB14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLUE","BK4578","BK4556","BK4139"],"gpt_icon":0},{"id":"2523635840","title":"Bluebird Bio Reviewing Competing Buyout Offer From Ayrmid for Up to $110.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2523635840","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523635840?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:55","pubTimestamp":1743195300,"startTime":"0","endTime":"0","summary":"Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon reaching a net sales milestone.The offer is about 10% higher than Bluebird's closing share price of $4.08 on Friday and a premium to a previous offer from two buyout firms that offered to pay $3 a share upfront for the company. The stock rose 10.5% in late trading to $4.51.Bluebird in February entered into an agreement with global investment firms Carlyle and SK Capital Partners to be acquired and taken private for up to $96 million in a mix of cash and shares. In addition to the $3 per share offer, the deal also proposed a one-time contingent value right payment of $6.84 a share, which would be payable upo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4578","BLUE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54}]}}